Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EASL position paper on preclinical models of steatotic liver disease.

Journal of hepatology·2026
Same author

Integrated multi-omics identifies distinct macrophage alterations during progression of metabolic dysfunction-associated steatohepatitis.

Nature genetics·2026
Same author

The use of pharmacotherapies in non-cirrhotic metabolic dysfunction-associated steatohepatitis: a UK expert consensus.

The lancet. Gastroenterology & hepatology·2026
Same author

Erratum to 'Hot and cold fibrosis: The role of serum biomarkers to assess immune mechanisms and ECM-cell interactions in human fibrosis' [J Hepatol 83 (2025) 239-257].

Journal of hepatology·2026
Same author

The Elucidating Pathways of Steatohepatitis (EPoS) staging system: A reproducible 7-tiered fibrosis scoring system in MASLD.

JHEP reports : innovation in hepatology·2026
Same author

Food Insecurity Is Highly Prevalent Amongst Patients With Chronic Liver Disease in Northern England: A Cross-Sectional Analysis.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2025

Related Experiment Video

Updated: Nov 9, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K

NAFLD-Associated HCC: Progress and Opportunities.

Daniel Geh1, Quentin M Anstee2,3, Helen L Reeves2,3,4

  • 1Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Journal of Hepatocellular Carcinoma
|April 15, 2021
PubMed
Summary
This summary is machine-generated.

Nonalcoholic fatty liver disease (NAFLD) is increasingly linked to liver cancer (hepatocellular carcinoma or HCC), especially in older, sicker patients. Ongoing research aims to improve early detection and develop targeted therapies for NAFLD-associated HCC.

Keywords:
HCCNAFLDbiomarkershepatocellular carcinomaimmunotherapyliver cirrhosisnonalcoholic fatty liver diseasepreventionsystemic therapy

More Related Videos

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K

Related Experiment Videos

Last Updated: Nov 9, 2025

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.6K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.4K
Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish
09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

3.8K

Area of Science:

  • Hepatology and Oncology
  • Metabolic Syndrome Research

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is a growing epidemic linked to metabolic syndrome.
  • NAFLD is a leading cause of liver cancer (hepatocellular carcinoma, HCC), often diagnosed at advanced stages in older patients with comorbidities.
  • The prognosis for NAFLD-associated HCC is poor, with uncertain benefits from standard treatments.

Purpose of the Study:

  • To review the current understanding of NAFLD-associated HCC pathogenesis.
  • To highlight recent advances in identifying high-risk patients and developing targeted therapies.
  • To discuss the evolving landscape of HCC treatment, including new systemic therapies.

Main Methods:

  • Literature review of NAFLD and HCC pathogenesis.
  • Analysis of recent clinical trial data and real-world evidence.
  • Discussion of emerging biomarkers and therapeutic strategies.

Main Results:

  • NAFLD progression to steatohepatitis and cirrhosis increases HCC risk.
  • New systemic therapies, like atezolizumab and bevacizumab, are transforming HCC treatment.
  • Lifestyle modifications and chemoprevention are being explored for HCC prevention.

Conclusions:

  • Understanding NAFLD-HCC drivers is crucial for developing biomarkers and targeted treatments.
  • Advances in systemic therapy offer new hope for patients with NAFLD-associated HCC.
  • Continued research and data analysis are essential to optimize care for this growing patient population.